David J Diemert

Summary

Affiliation: Sabin Vaccine Institute
Country: USA

Publications

  1. pmc Prevention and self-treatment of traveler's diarrhea
    David J Diemert
    Human Hookworm Vaccine Initiative, Sabin Vaccine Institute, 1889 F St NW, Suite 200S, Washington, DC 20006, USA
    Clin Microbiol Rev 19:583-94. 2006
  2. pmc Health education through analogies: preparation of a community for clinical trials of a vaccine against hookworm in an endemic area of Brazil
    Maria Flavia Gazzinelli
    School of Nursing, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
    PLoS Negl Trop Dis 4:e749. 2010
  3. doi request reprint Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths
    David J Diemert
    Albert B Sabin Vaccine Institute, Washington, DC 20037, USA
    J Allergy Clin Immunol 130:169-76.e6. 2012
  4. doi request reprint Randomized, placebo-controlled, double-blind trial of the Na-ASP-2 hookworm vaccine in unexposed adults
    Jeffrey M Bethony
    Department of Microbiology, Immunology and Tropical Medicine, George Washington University Health Center, Washington, DC 20037, United States
    Vaccine 26:2408-17. 2008
  5. doi request reprint Developing vaccines to combat hookworm infection and intestinal schistosomiasis
    Peter J Hotez
    Department of Microbiology, Immunology, and Tropical Medicine, George Washington University, Washington, DC 20037, USA
    Nat Rev Microbiol 8:814-26. 2010
  6. doi request reprint Potency testing for the experimental Na-GST-1 hookworm vaccine
    Amar R Jariwala
    Albert B Sabin Vaccine Institute, Washington, DC, USA
    Expert Rev Vaccines 9:1219-30. 2010
  7. doi request reprint Hookworm vaccines
    David J Diemert
    Sabin Vaccine Institute, George Washington University, Washington, DC 20037, USA
    Clin Infect Dis 46:282-8. 2008
  8. ncbi request reprint Prevention and self-treatment of travelers' diarrhea
    David J Diemert
    Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook I, Room 1123, 5640 Fishers Lane, Rockville, MD 20852, USA
    Prim Care 29:843-55, vi(2). 2002

Collaborators

  • Peter J Hotez
  • Alex Loukas
  • Maria V Periago
  • Robert G Hamilton
  • Jason Mulvenna
  • Jeffrey M Bethony
  • Amar R Jariwala
  • Maria Flavia Gazzinelli
  • Jordan L Plieskatt
  • Leonardo Matoso
  • Luciana M Oliveira
  • Rodrigo Correa-Oliveira
  • Ami Shah Brown
  • Rita de Cassia Marques
  • Renato Avila
  • Lucas Lobato
  • Maria E Bottazzi
  • Brian Keegan
  • Helton Santiago
  • Suzanne Schuck
  • Aimee Desrosiers
  • David Parenti
  • Ricardo Fujiwara
  • Gary Simon

Detail Information

Publications8

  1. pmc Prevention and self-treatment of traveler's diarrhea
    David J Diemert
    Human Hookworm Vaccine Initiative, Sabin Vaccine Institute, 1889 F St NW, Suite 200S, Washington, DC 20006, USA
    Clin Microbiol Rev 19:583-94. 2006
    ..In the future, vaccines-several of which are in the advanced stages of clinical testing-may be added to the list of prophylactic measures...
  2. pmc Health education through analogies: preparation of a community for clinical trials of a vaccine against hookworm in an endemic area of Brazil
    Maria Flavia Gazzinelli
    School of Nursing, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
    PLoS Negl Trop Dis 4:e749. 2010
    ....
  3. doi request reprint Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths
    David J Diemert
    Albert B Sabin Vaccine Institute, Washington, DC 20037, USA
    J Allergy Clin Immunol 130:169-76.e6. 2012
    ..Vaccination of laboratory animals with recombinant Na-ASP-2 provides significant protection against challenge infections. In endemic areas antibodies to Na-ASP-2 are associated with reduced risk of heavy N americanus infections...
  4. doi request reprint Randomized, placebo-controlled, double-blind trial of the Na-ASP-2 hookworm vaccine in unexposed adults
    Jeffrey M Bethony
    Department of Microbiology, Immunology and Tropical Medicine, George Washington University Health Center, Washington, DC 20037, United States
    Vaccine 26:2408-17. 2008
    ....
  5. doi request reprint Developing vaccines to combat hookworm infection and intestinal schistosomiasis
    Peter J Hotez
    Department of Microbiology, Immunology, and Tropical Medicine, George Washington University, Washington, DC 20037, USA
    Nat Rev Microbiol 8:814-26. 2010
    ..New genomic, proteomic, immunological and X-ray crystallographic data have led to the discovery of several promising candidate vaccine antigens. Here, we describe recent progress in this field and the rationale for vaccine development...
  6. doi request reprint Potency testing for the experimental Na-GST-1 hookworm vaccine
    Amar R Jariwala
    Albert B Sabin Vaccine Institute, Washington, DC, USA
    Expert Rev Vaccines 9:1219-30. 2010
    ..Our experience is that much of the existing information is proprietary and needs to be pulled together in a single source to aid in our overall understanding of potency testing...
  7. doi request reprint Hookworm vaccines
    David J Diemert
    Sabin Vaccine Institute, George Washington University, Washington, DC 20037, USA
    Clin Infect Dis 46:282-8. 2008
    ..Plans call for eventual development of a vaccine that will combine at least 2 hookworm antigens--one targeting the larval stage of the life cycle and another targeting the adult worm living in the gastrointestinal tract...
  8. ncbi request reprint Prevention and self-treatment of travelers' diarrhea
    David J Diemert
    Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook I, Room 1123, 5640 Fishers Lane, Rockville, MD 20852, USA
    Prim Care 29:843-55, vi(2). 2002
    ..If diarrhea does develop despite precautions, effective treatment, usually a combination of an antibiotic and an antimotility agent, can be taken along and started by the traveler at the onset of symptoms...